NR 546 ADVANCED PHARMACOLOGY MIDTERM EXAM
WEEK 4 2026/2027 | Tested Questions with Revised Answers
| Across the Lifespan | Pass Guaranteed - A+ Graded
Q1: Which neurotransmitter is primarily synthesized from the amino acid tryptophan and
is the target of selective serotonin reuptake inhibitors (SSRIs)?
A. Dopamine
B. Norepinephrine
C. Serotonin (5-HT)
D. Gamma-aminobutyric acid (GABA)
Correct Answer: C
Rationale: Serotonin (5-hydroxytryptamine, 5-HT) is synthesized from the essential
amino acid tryptophan through hydroxylation to 5-hydroxytryptophan (5-HTP), then
decarboxylation to serotonin. SSRIs selectively block the serotonin transporter (SERT) at
the presynaptic membrane, increasing synaptic 5-HT availability. Option A (Dopamine) is
synthesized from tyrosine (L-DOPA pathway). Option B (Norepinephrine) is synthesized
from dopamine via dopamine β-hydroxylase. Option D (GABA) is synthesized from
glutamate via glutamic acid decarboxylase (GAD). Understanding precursor amino
acids and synthetic pathways is fundamental for NR 546 neurobiology competency and
predicting drug-nutrient interactions.
,Q2: [SATA] Which of the following factors can increase the permeability of the
blood-brain barrier (BBB) and potentially alter CNS drug distribution? Select all that
apply.
A. Advanced age
B. Hypertension
C. Inflammation or infection
D. Chronic stress
E. Pregnancy
Correct Answers: A, C, D [CORRECT]
Rationale: The blood-brain barrier (tight junctions between capillary endothelial cells,
astrocyte end-feet, pericytes) can be compromised by: A—Advanced age (decreased
BBB integrity, increased permeability); C—Inflammation/infection (cytokines disrupt
tight junctions, allowing immune cells and drugs to penetrate); D—Chronic stress
(elevated glucocorticoids alter BBB permeability). Option B (Hypertension) is generally
incorrect—acute severe hypertension can disrupt BBB, but chronic controlled
hypertension does not significantly increase permeability; however, chronic
hypertension can cause vascular remodeling. Option E (Pregnancy)—the BBB remains
relatively intact, though physiologic changes occur; the placental barrier is more
relevant for fetal exposure. BBB permeability affects drug CNS penetration: lipophilic
drugs (most psychotropics) cross easily; efflux transporters (P-glycoprotein) actively
pump drugs out. Inflammation increases CNS side effects and therapeutic drug access.
Q3: A patient is prescribed sertraline 50 mg daily for major depressive disorder. The NP
understands that steady-state plasma concentrations will be achieved in approximately:
,A. 1-2 days
B. 3-5 days
C. 1-2 weeks
D. 4-6 weeks
Correct Answer: C
Rationale: Sertraline half-life (t½) is approximately 26 hours (range 22-36 hours), with its
active metabolite desmethylsertraline t½ ~62-104 hours. Steady-state (where drug
elimination equals administration rate) is achieved in 4-5 half-lives: ~5-6 days for parent
drug, but clinically 1-2 weeks considering active metabolite accumulation and receptor
adaptation. Option A (1-2 days) is insufficient for any SSRI. Option B (3-5 days)
approaches steady-state for parent drug only. Option D (4-6 weeks) is therapeutic
response timeline, not pharmacokinetic steady-state. This distinction is critical:
steady-state (pharmacokinetic) ≠ therapeutic response (pharmacodynamic, requires
receptor downregulation and neuroplastic changes). Dose adjustments should occur no
more frequently than every 1-2 weeks.
Q4: Which CYP450 enzyme is responsible for the metabolism of approximately 50% of
all psychotropic medications and is the primary metabolic pathway for sertraline,
citalopram, and diazepam?
A. CYP1A2
B. CYP2C19
C. CYP2D6
D. CYP3A4
, Correct Answer: D
Rationale: CYP3A4 is the most abundant hepatic CYP enzyme (~30% of total),
metabolizes ~50% of all drugs, and is the primary pathway for sertraline
(N-demethylation), citalopram (N-demethylation), diazepam (N-demethylation and
hydroxylation), and numerous other psychotropics (alprazolam, midazolam, buspirone,
quetiapine, lurasidone, ziprasidone). Option A (CYP1A2) metabolizes clozapine,
olanzapine, duloxetine; induced by smoking, inhibited by fluvoxamine. Option B
(CYP2C19) metabolizes citalopram, escitalopram, sertraline (partial), diazepam,
phenytoin; extensive polymorphism. Option C (CYP2D6) metabolizes fluoxetine,
paroxetine, venlafaxine, trazodone, risperidone, haloperidol, atomoxetine; major
polymorphic variability (poor, intermediate, extensive, ultra-rapid metabolizers).
Understanding CYP450 profiles is essential for predicting drug-drug interactions and
individualized dosing in NR 546.
Q5: A patient on fluoxetine 40 mg daily presents with agitation, confusion, diaphoresis,
tremor, hyperreflexia, and diarrhea. Vital signs show HR 118, BP 160/100, T 38.5°C. The
NP recognizes this as serotonin syndrome. Which medication combination is the MOST
likely cause?
A. Fluoxetine + lithium
B. Fluoxetine + tramadol
C. Fluoxetine + lamotrigine
D. Fluoxetine + gabapentin
Correct Answer: B
WEEK 4 2026/2027 | Tested Questions with Revised Answers
| Across the Lifespan | Pass Guaranteed - A+ Graded
Q1: Which neurotransmitter is primarily synthesized from the amino acid tryptophan and
is the target of selective serotonin reuptake inhibitors (SSRIs)?
A. Dopamine
B. Norepinephrine
C. Serotonin (5-HT)
D. Gamma-aminobutyric acid (GABA)
Correct Answer: C
Rationale: Serotonin (5-hydroxytryptamine, 5-HT) is synthesized from the essential
amino acid tryptophan through hydroxylation to 5-hydroxytryptophan (5-HTP), then
decarboxylation to serotonin. SSRIs selectively block the serotonin transporter (SERT) at
the presynaptic membrane, increasing synaptic 5-HT availability. Option A (Dopamine) is
synthesized from tyrosine (L-DOPA pathway). Option B (Norepinephrine) is synthesized
from dopamine via dopamine β-hydroxylase. Option D (GABA) is synthesized from
glutamate via glutamic acid decarboxylase (GAD). Understanding precursor amino
acids and synthetic pathways is fundamental for NR 546 neurobiology competency and
predicting drug-nutrient interactions.
,Q2: [SATA] Which of the following factors can increase the permeability of the
blood-brain barrier (BBB) and potentially alter CNS drug distribution? Select all that
apply.
A. Advanced age
B. Hypertension
C. Inflammation or infection
D. Chronic stress
E. Pregnancy
Correct Answers: A, C, D [CORRECT]
Rationale: The blood-brain barrier (tight junctions between capillary endothelial cells,
astrocyte end-feet, pericytes) can be compromised by: A—Advanced age (decreased
BBB integrity, increased permeability); C—Inflammation/infection (cytokines disrupt
tight junctions, allowing immune cells and drugs to penetrate); D—Chronic stress
(elevated glucocorticoids alter BBB permeability). Option B (Hypertension) is generally
incorrect—acute severe hypertension can disrupt BBB, but chronic controlled
hypertension does not significantly increase permeability; however, chronic
hypertension can cause vascular remodeling. Option E (Pregnancy)—the BBB remains
relatively intact, though physiologic changes occur; the placental barrier is more
relevant for fetal exposure. BBB permeability affects drug CNS penetration: lipophilic
drugs (most psychotropics) cross easily; efflux transporters (P-glycoprotein) actively
pump drugs out. Inflammation increases CNS side effects and therapeutic drug access.
Q3: A patient is prescribed sertraline 50 mg daily for major depressive disorder. The NP
understands that steady-state plasma concentrations will be achieved in approximately:
,A. 1-2 days
B. 3-5 days
C. 1-2 weeks
D. 4-6 weeks
Correct Answer: C
Rationale: Sertraline half-life (t½) is approximately 26 hours (range 22-36 hours), with its
active metabolite desmethylsertraline t½ ~62-104 hours. Steady-state (where drug
elimination equals administration rate) is achieved in 4-5 half-lives: ~5-6 days for parent
drug, but clinically 1-2 weeks considering active metabolite accumulation and receptor
adaptation. Option A (1-2 days) is insufficient for any SSRI. Option B (3-5 days)
approaches steady-state for parent drug only. Option D (4-6 weeks) is therapeutic
response timeline, not pharmacokinetic steady-state. This distinction is critical:
steady-state (pharmacokinetic) ≠ therapeutic response (pharmacodynamic, requires
receptor downregulation and neuroplastic changes). Dose adjustments should occur no
more frequently than every 1-2 weeks.
Q4: Which CYP450 enzyme is responsible for the metabolism of approximately 50% of
all psychotropic medications and is the primary metabolic pathway for sertraline,
citalopram, and diazepam?
A. CYP1A2
B. CYP2C19
C. CYP2D6
D. CYP3A4
, Correct Answer: D
Rationale: CYP3A4 is the most abundant hepatic CYP enzyme (~30% of total),
metabolizes ~50% of all drugs, and is the primary pathway for sertraline
(N-demethylation), citalopram (N-demethylation), diazepam (N-demethylation and
hydroxylation), and numerous other psychotropics (alprazolam, midazolam, buspirone,
quetiapine, lurasidone, ziprasidone). Option A (CYP1A2) metabolizes clozapine,
olanzapine, duloxetine; induced by smoking, inhibited by fluvoxamine. Option B
(CYP2C19) metabolizes citalopram, escitalopram, sertraline (partial), diazepam,
phenytoin; extensive polymorphism. Option C (CYP2D6) metabolizes fluoxetine,
paroxetine, venlafaxine, trazodone, risperidone, haloperidol, atomoxetine; major
polymorphic variability (poor, intermediate, extensive, ultra-rapid metabolizers).
Understanding CYP450 profiles is essential for predicting drug-drug interactions and
individualized dosing in NR 546.
Q5: A patient on fluoxetine 40 mg daily presents with agitation, confusion, diaphoresis,
tremor, hyperreflexia, and diarrhea. Vital signs show HR 118, BP 160/100, T 38.5°C. The
NP recognizes this as serotonin syndrome. Which medication combination is the MOST
likely cause?
A. Fluoxetine + lithium
B. Fluoxetine + tramadol
C. Fluoxetine + lamotrigine
D. Fluoxetine + gabapentin
Correct Answer: B
